These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18066027)

  • 1. Isotype selection in antibody engineering.
    Salfeld JG
    Nat Biotechnol; 2007 Dec; 25(12):1369-72. PubMed ID: 18066027
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineering antibodies for biosensor technologies.
    Goodchild S; Love T; Hopkins N; Mayers C
    Adv Appl Microbiol; 2006; 58():185-226. PubMed ID: 16509447
    [No Abstract]   [Full Text] [Related]  

  • 3. Tailoring natural effector functions. Antibody engineering beyond humanization.
    Brekke OH; Thommesen JE
    Methods Mol Biol; 2003; 207():383-91. PubMed ID: 12412487
    [No Abstract]   [Full Text] [Related]  

  • 4. Aglycosylated antibodies and the methods of making and using them: WO2008030564.
    Jefferis R
    Expert Opin Ther Pat; 2009 Jan; 19(1):101-5. PubMed ID: 19441902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of humanized IgGs in glycoengineered Pichia pastoris.
    Li H; Sethuraman N; Stadheim TA; Zha D; Prinz B; Ballew N; Bobrowicz P; Choi BK; Cook WJ; Cukan M; Houston-Cummings NR; Davidson R; Gong B; Hamilton SR; Hoopes JP; Jiang Y; Kim N; Mansfield R; Nett JH; Rios S; Strawbridge R; Wildt S; Gerngross TU
    Nat Biotechnol; 2006 Feb; 24(2):210-5. PubMed ID: 16429149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and application of antibody cysteine variants.
    Voynov V; Chennamsetty N; Kayser V; Wallny HJ; Helk B; Trout BL
    Bioconjug Chem; 2010 Feb; 21(2):385-92. PubMed ID: 20092294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving an anti-toxin antibody.
    Presta L
    Nat Biotechnol; 2007 Jan; 25(1):63-5. PubMed ID: 17211401
    [No Abstract]   [Full Text] [Related]  

  • 8. Prestige Antibodies--monospecific antibodies designed for immunohistochemical analysis.
    Gunnerås S; Agaton C; Djerbi S; Hansson M
    Biotechniques; 2008 May; 44(6):825-8. PubMed ID: 18476838
    [No Abstract]   [Full Text] [Related]  

  • 9. Engineered single chain antibody fragments for radioimmunotherapy.
    Huhalov A; Chester KA
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and manufacture of monoclonal antibodies for radioimmunotherapy.
    Hale G; Berrie E; Bird P
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor.
    Kai M; Motoki K; Yoshida H; Emuta C; Chisaka Y; Tsuruhata K; Endo C; Muto M; Shimabe M; Nishiyama U; Hagiwara T; Matsumoto A; Miyazaki H; Kataoka S
    Nat Biotechnol; 2008 Feb; 26(2):209-11. PubMed ID: 18157117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of target-specific recombinant human polyclonal antibodies in mammalian cells.
    Wiberg FC; Rasmussen SK; Frandsen TP; Rasmussen LK; Tengbjerg K; Coljee VW; Sharon J; Yang CY; Bregenholt S; Nielsen LS; Haurum JS; Tolstrup AB
    Biotechnol Bioeng; 2006 Jun; 94(2):396-405. PubMed ID: 16596663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tunable antibodies.
    Weiner LM; Carter P
    Nat Biotechnol; 2005 May; 23(5):556-7. PubMed ID: 15877072
    [No Abstract]   [Full Text] [Related]  

  • 15. Humanized antibodies as potential drugs for therapeutic use.
    Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C
    Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display.
    Mazor Y; Van Blarcom T; Iverson BL; Georgiou G
    Nat Protoc; 2008; 3(11):1766-77. PubMed ID: 18948976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies in the breakdown lane.
    Blumberg RS; Lencer WI
    Nat Biotechnol; 2005 Oct; 23(10):1232-4. PubMed ID: 16211062
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells.
    Nielsen LK; Norderhaug L; Sandlie I; Dziegiel MH
    APMIS; 2006 May; 114(5):345-51. PubMed ID: 16725010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When binding is enough: nonactivating antibody formats.
    Labrijn AF; Aalberse RC; Schuurman J
    Curr Opin Immunol; 2008 Aug; 20(4):479-85. PubMed ID: 18577454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized antibodies for therapy.
    Co MS; Queen C
    Nature; 1991 Jun; 351(6326):501-2. PubMed ID: 2046753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.